These combinatory therapies are important, as HGF/c-Met signaling has been implicated in the conferral of resistance to BRAF and MEK inhibitors, and c-Met inhibitors hold promise as potential additions to these therapies to promote tumor regression [66]. Here, MAP2K7 is linked to neoplasm.